GoodRx (NASDAQ:GDRX) Rating Increased to Buy at Wall Street Zen

GoodRx (NASDAQ:GDRX - Get Free Report) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a report issued on Saturday.

• Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?

Several other equities analysts also recently issued reports on GDRX. UBS Group upped their price objective on shares of GoodRx from $2.50 to $3.75 and gave the company a "neutral" rating in a research note on Thursday. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $4.00 target price on shares of GoodRx in a research note on Friday, August 7th. TD Cowen boosted their price target on GoodRx from $4.00 to $5.00 and gave the company a "buy" rating in a report on Tuesday. Leerink Partners set a $5.00 price target on GoodRx in a research note on Thursday, August 6th. Finally, Weiss Ratings raised GoodRx from a "sell (d)" rating to a "sell (d+)" rating in a research note on Friday, August 7th. Four analysts have rated the stock with a Buy rating, six have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $4.14.

Read Our Latest Research Report on GoodRx

GoodRx Trading Up 0.3%

• This healthcare stock making a buzz with 160% growth

Shares of GDRX stock opened at $3.73 on Friday. The firm has a 50-day moving average price of $3.03 and a 200 day moving average price of $2.59. GoodRx has a twelve month low of $1.77 and a twelve month high of $5.81. The company has a market capitalization of $1.28 billion, a price-to-earnings ratio of 93.27, a PEG ratio of 1.77 and a beta of 1.60. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.74.

GoodRx (NASDAQ:GDRX - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $0.08 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.08. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The company had revenue of $200.41 million for the quarter, compared to analyst estimates of $193.23 million. The firm's quarterly revenue was down 1.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.09 EPS. Research analysts forecast that GoodRx will post 0.16 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

• Gene therapy: Why does it cost millions for a single treatment?

Several large investors have recently modified their holdings of GDRX. AQR Capital Management LLC grew its holdings in GoodRx by 124.4% in the first quarter. AQR Capital Management LLC now owns 282,320 shares of the company's stock valued at $1,245,000 after purchasing an additional 156,482 shares during the period. Goldman Sachs Group Inc. increased its position in GoodRx by 7.5% during the first quarter. Goldman Sachs Group Inc. now owns 783,378 shares of the company's stock worth $3,455,000 after purchasing an additional 54,783 shares during the last quarter. Jane Street Group LLC purchased a new position in GoodRx during the first quarter worth approximately $370,000. Creative Planning purchased a new position in GoodRx during the second quarter worth approximately $93,000. Finally, Cetera Investment Advisers acquired a new position in shares of GoodRx in the 2nd quarter valued at $50,000. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

GoodRx Company Profile

(Get Free Report)

GoodRx Holdings, Inc NASDAQ: GDRX operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.

Read More

• Five stocks we like better than GoodRx
• Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
• Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
• NVIDIA's $500 Billion GPU Financing Deal Fuels Path Toward $270
• Sandisk’s Margins Look Like Software. Can They Last?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in GoodRx Right Now?

Before you consider GoodRx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list.

While GoodRx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here